profit from every $100 of sales.
$0$100
argenx
$960.04-2.17% today
+7.7% in 1 year
1-year low $663.931-year high $1,058.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $46.73 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What argenx sold, what it kept, and what it did with the cash.
Sales went from $411 million in 2022 to $4.15 billion in 2025, with $1.29 billion of profit last year.
SalesProfit
argenx vs. similar companies
argenx grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| argenx | 46.7× · Expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
Compare argenx with AbbVie · Johnson & Johnson · Eli Lilly · Merck & · Roche · UnitedHealth
AI analysis
An AI analyst reads argenx's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 411 | 1,226 | 2,190 | 4,153 | |
| 381 | 1,108 | 1,963 | 3,703 | |
| -724 | -421 | -18 | 1,055 | |
| -623 | -192 | 105 | 1,311 | |
| -710 | -295 | 833 | 1,292 | |
| -13.05 | -5.16 | 12.78 | 19.57 | |
| 92.8% | 90.4% | 89.6% | 89.1% | |
| -176.2% | -34.3% | -0.8% | 25.4% | |
| -172.8% | -24.1% | 38.0% | 31.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,134 | 4,542 | 6,203 | 8,683 |
| Cash | 801 | 2,049 | 1,500 | 3,491 |
| Total debt | 12 | 20 | 39 | 47 |
| Total liabilities | 321 | 445 | 704 | 1,360 |
| 2,814 | 4,098 | 5,498 | 7,323 | |
| 54 | 57 | 65 | 66 | |
| -20.3% | -5.8% | 1.3% | 13.7% | |
| -25.2% | -7.2% | 15.2% | 17.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -863 | -420 | -83 | 685 | |
| 104 | 44 | 68 | 112 | |
| -967 | -464 | -151 | 574 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 157 | 233 | 235 | 248 |
Valuation
- 46.7×
- 36.5×
- –
- 6.8×
- 14.5×
- 105.3×
- 43.4×
- 0.9%
- 2.1%
- 0.0%
Profitability
- 89.1%
- 25.4%
- 31.1%
- 28.6%
- 11.7%
- -3.2%
- 16.8%
- 13.0%
- 11.8%
- 31.4%
Growth
- +116.2%
- –
- +659.0%
- –
- +4.7%
Financial health
- -3.5×
- 0.01
- 1.0%
- 292.6×
- 5.23
- 4.87
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 22%of 952
Top 13%of 884
Bottom 26%of 601
Top 5%of 886
Bottom 47%of 987
What analysts expect
- Average price target
- $1,065.89
- Range
- $858.00 – $1,317.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 5.90 | 6.00 | −1.7% |
| Oct 30, 2025 | 5.18 | 4.37 | +18.5% |
| May 8, 2025 | 2.58 | 0.98 | +163.3% |
| Mar 31, 2025 | 2.58 | – | – |
| Oct 31, 2024 | 1.39 | 0.10 | +1,290.0% |
| Sep 30, 2024 | 1.39 | – | – |
| May 9, 2024 | -1.04 | -0.71 | −46.5% |
| Mar 31, 2024 | -1.04 | – | – |
News
argenx Q3 revenue and profit risesSeeking Alpha · Oct 22, 2026Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger StoryYahoo Finance · Aug 26, 2026Argenx cut to hold at Deutsche Bank following share price runSeeking Alpha · Aug 24, 2026Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositisSeeking Alpha · Aug 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
35No pass
Philip Fisher
54No pass
Peter Lynch
100Pass
Joel Greenblatt
13No pass
Charlie Munger
48No pass
Terry Smith
41No pass
Questions about argenx
Is argenx a good stock to buy?
A strong, very profitable business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the argenx AI analysis
What does argenx do?
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. It is in Biotechnology, based in Amsterdam, Netherlands, with 1,863 employees.
Does argenx pay a dividend?
No. argenx does not pay a dividend at the moment.
Is argenx stock halal?
Yes. argenx passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has argenx stock done over the past year?
Up 7.7% over the past twelve months, to $960.04. It traded between $663.93 and $1,058.90 and is 9.3% below its high.
Who are argenx's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with argenx's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.